Quest Diagnostics Incorporated
Quest Diagnostics Incorporated DGX Peers
See (DGX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGX | $175.93 | -0.58% | 19.64B | 22.24 | $7.91 | +1.74% |
| DHR-PB | $1,261.26 | -0.78% | 916.76B | 146.01 | $8.64 | +0.57% |
| TMO | $432.51 | +7.29% | 163.27B | 25.37 | $17.05 | +0.37% |
| DHR | $200.92 | +5.90% | 143.79B | 38.94 | $5.16 | +0.57% |
| IDXX | $509.53 | +3.63% | 40.98B | 47.18 | $10.80 | N/A |
| A | $115.61 | +8.12% | 32.96B | 26.46 | $4.37 | +0.84% |
| IQV | $156.13 | +4.79% | 27.01B | 21.30 | $7.33 | N/A |
| MTD | $1,176.00 | +8.79% | 24.44B | 29.39 | $40.02 | N/A |
| WAT | $366.66 | +6.57% | 21.82B | 33.27 | $11.02 | N/A |
| NTRA | $157.29 | +3.51% | 21.32B | -102.14 | -$1.54 | N/A |
Stock Comparison
DGX vs DHR-PB Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, DHR-PB has a market cap of 916.76B. Regarding current trading prices, DGX is priced at $175.93, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, DGX's ROE is +0.13%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, DGX is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs TMO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, TMO has a market cap of 163.27B. Regarding current trading prices, DGX is priced at $175.93, while TMO trades at $432.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas TMO's P/E ratio is 25.37. In terms of profitability, DGX's ROE is +0.13%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DGX is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs DHR Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, DHR has a market cap of 143.79B. Regarding current trading prices, DGX is priced at $175.93, while DHR trades at $200.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas DHR's P/E ratio is 38.94. In terms of profitability, DGX's ROE is +0.13%, compared to DHR's ROE of +0.07%. Regarding short-term risk, DGX is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs IDXX Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, IDXX has a market cap of 40.98B. Regarding current trading prices, DGX is priced at $175.93, while IDXX trades at $509.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas IDXX's P/E ratio is 47.18. In terms of profitability, DGX's ROE is +0.13%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, DGX is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs A Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, A has a market cap of 32.96B. Regarding current trading prices, DGX is priced at $175.93, while A trades at $115.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas A's P/E ratio is 26.46. In terms of profitability, DGX's ROE is +0.13%, compared to A's ROE of +0.21%. Regarding short-term risk, DGX is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs IQV Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, IQV has a market cap of 27.01B. Regarding current trading prices, DGX is priced at $175.93, while IQV trades at $156.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas IQV's P/E ratio is 21.30. In terms of profitability, DGX's ROE is +0.13%, compared to IQV's ROE of +0.21%. Regarding short-term risk, DGX is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs MTD Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, MTD has a market cap of 24.44B. Regarding current trading prices, DGX is priced at $175.93, while MTD trades at $1,176.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas MTD's P/E ratio is 29.39. In terms of profitability, DGX's ROE is +0.13%, compared to MTD's ROE of +1.21%. Regarding short-term risk, DGX is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs WAT Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, WAT has a market cap of 21.82B. Regarding current trading prices, DGX is priced at $175.93, while WAT trades at $366.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas WAT's P/E ratio is 33.27. In terms of profitability, DGX's ROE is +0.13%, compared to WAT's ROE of +0.39%. Regarding short-term risk, DGX is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs NTRA Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NTRA has a market cap of 21.32B. Regarding current trading prices, DGX is priced at $175.93, while NTRA trades at $157.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NTRA's P/E ratio is -102.14. In terms of profitability, DGX's ROE is +0.13%, compared to NTRA's ROE of -0.21%. Regarding short-term risk, DGX is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PKI Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PKI has a market cap of 14.46B. Regarding current trading prices, DGX is priced at $175.93, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PKI's P/E ratio is 41.45. In terms of profitability, DGX's ROE is +0.13%, compared to PKI's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs ILMN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ILMN has a market cap of 12.91B. Regarding current trading prices, DGX is priced at $175.93, while ILMN trades at $81.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ILMN's P/E ratio is -10.61. In terms of profitability, DGX's ROE is +0.13%, compared to ILMN's ROE of -0.42%. Regarding short-term risk, DGX is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs RVTY Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, RVTY has a market cap of 11.61B. Regarding current trading prices, DGX is priced at $175.93, while RVTY trades at $98.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas RVTY's P/E ratio is 40.71. In terms of profitability, DGX's ROE is +0.13%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, DGX is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs ICLR Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ICLR has a market cap of 11.32B. Regarding current trading prices, DGX is priced at $175.93, while ICLR trades at $140.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ICLR's P/E ratio is 15.27. In terms of profitability, DGX's ROE is +0.13%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, DGX is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs TEM Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, TEM has a market cap of 10.54B. Regarding current trading prices, DGX is priced at $175.93, while TEM trades at $62.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas TEM's P/E ratio is -12.15. In terms of profitability, DGX's ROE is +0.13%, compared to TEM's ROE of +21.50%. Regarding short-term risk, DGX is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs EXAS Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, EXAS has a market cap of 10.07B. Regarding current trading prices, DGX is priced at $175.93, while EXAS trades at $53.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas EXAS's P/E ratio is -9.66. In terms of profitability, DGX's ROE is +0.13%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, DGX is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs QGEN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, QGEN has a market cap of 9.28B. Regarding current trading prices, DGX is priced at $175.93, while QGEN trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas QGEN's P/E ratio is 113.00. In terms of profitability, DGX's ROE is +0.13%, compared to QGEN's ROE of +0.02%. Regarding short-term risk, DGX is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs MEDP Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, MEDP has a market cap of 9.02B. Regarding current trading prices, DGX is priced at $175.93, while MEDP trades at $313.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas MEDP's P/E ratio is 23.93. In terms of profitability, DGX's ROE is +0.13%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, DGX is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CRL Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CRL has a market cap of 7.03B. Regarding current trading prices, DGX is priced at $175.93, while CRL trades at $143.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CRL's P/E ratio is 681.38. In terms of profitability, DGX's ROE is +0.13%, compared to CRL's ROE of +0.00%. Regarding short-term risk, DGX is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs GH Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, GH has a market cap of 5.16B. Regarding current trading prices, DGX is priced at $175.93, while GH trades at $41.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas GH's P/E ratio is -12.29. In terms of profitability, DGX's ROE is +0.13%, compared to GH's ROE of +3.69%. Regarding short-term risk, DGX is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs SYNH Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, SYNH has a market cap of 4.46B. Regarding current trading prices, DGX is priced at $175.93, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DGX's ROE is +0.13%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs RDNT Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, RDNT has a market cap of 4.22B. Regarding current trading prices, DGX is priced at $175.93, while RDNT trades at $57.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas RDNT's P/E ratio is 1425.75. In terms of profitability, DGX's ROE is +0.13%, compared to RDNT's ROE of +0.02%. Regarding short-term risk, DGX is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs SHC Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, SHC has a market cap of 3.35B. Regarding current trading prices, DGX is priced at $175.93, while SHC trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas SHC's P/E ratio is 73.88. In terms of profitability, DGX's ROE is +0.13%, compared to SHC's ROE of +0.06%. Regarding short-term risk, DGX is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs OLK Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, OLK has a market cap of 3.24B. Regarding current trading prices, DGX is priced at $175.93, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas OLK's P/E ratio is -96.59. In terms of profitability, DGX's ROE is +0.13%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DGX is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs TWST Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, TWST has a market cap of 1.97B. Regarding current trading prices, DGX is priced at $175.93, while TWST trades at $32.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas TWST's P/E ratio is -10.14. In terms of profitability, DGX's ROE is +0.13%, compared to TWST's ROE of -0.41%. Regarding short-term risk, DGX is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs VIVO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, VIVO has a market cap of 1.49B. Regarding current trading prices, DGX is priced at $175.93, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas VIVO's P/E ratio is 21.09. In terms of profitability, DGX's ROE is +0.13%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, DGX is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs NEOG Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NEOG has a market cap of 1.41B. Regarding current trading prices, DGX is priced at $175.93, while NEOG trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NEOG's P/E ratio is -2.91. In terms of profitability, DGX's ROE is +0.13%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, DGX is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs GRAL Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, GRAL has a market cap of 1.27B. Regarding current trading prices, DGX is priced at $175.93, while GRAL trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas GRAL's P/E ratio is -0.57. In terms of profitability, DGX's ROE is +0.13%, compared to GRAL's ROE of -0.70%. Regarding short-term risk, DGX is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs OPK Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, OPK has a market cap of 999.25M. Regarding current trading prices, DGX is priced at $175.93, while OPK trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas OPK's P/E ratio is -21.00. In terms of profitability, DGX's ROE is +0.13%, compared to OPK's ROE of -0.03%. Regarding short-term risk, DGX is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs CDNA Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CDNA has a market cap of 912.05M. Regarding current trading prices, DGX is priced at $175.93, while CDNA trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CDNA's P/E ratio is 14.62. In terms of profitability, DGX's ROE is +0.13%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, DGX is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs FLGT Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, FLGT has a market cap of 612.53M. Regarding current trading prices, DGX is priced at $175.93, while FLGT trades at $20.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas FLGT's P/E ratio is -15.13. In terms of profitability, DGX's ROE is +0.13%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, DGX is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs GRALV Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, GRALV has a market cap of 579.39M. Regarding current trading prices, DGX is priced at $175.93, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas GRALV's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.13%, compared to GRALV's ROE of N/A. Regarding short-term risk, DGX is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CSTL Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CSTL has a market cap of 491.84M. Regarding current trading prices, DGX is priced at $175.93, while CSTL trades at $17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CSTL's P/E ratio is -89.66. In terms of profitability, DGX's ROE is +0.13%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, DGX is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PSNL Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PSNL has a market cap of 450.46M. Regarding current trading prices, DGX is priced at $175.93, while PSNL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PSNL's P/E ratio is -3.72. In terms of profitability, DGX's ROE is +0.13%, compared to PSNL's ROE of -0.54%. Regarding short-term risk, DGX is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs LAB Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, LAB has a market cap of 440.59M. Regarding current trading prices, DGX is priced at $175.93, while LAB trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas LAB's P/E ratio is -2.23. In terms of profitability, DGX's ROE is +0.13%, compared to LAB's ROE of -0.27%. Regarding short-term risk, DGX is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CO has a market cap of 400.08M. Regarding current trading prices, DGX is priced at $175.93, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CO's P/E ratio is 5.06. In terms of profitability, DGX's ROE is +0.13%, compared to CO's ROE of +0.18%. Regarding short-term risk, DGX is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs MYGN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, MYGN has a market cap of 391.75M. Regarding current trading prices, DGX is priced at $175.93, while MYGN trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas MYGN's P/E ratio is -3.01. In terms of profitability, DGX's ROE is +0.13%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, DGX is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs FLDM Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, FLDM has a market cap of 294.19M. Regarding current trading prices, DGX is priced at $175.93, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DGX's ROE is +0.13%, compared to FLDM's ROE of -0.27%. Regarding short-term risk, DGX is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs STIM Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, STIM has a market cap of 272.50M. Regarding current trading prices, DGX is priced at $175.93, while STIM trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas STIM's P/E ratio is -3.00. In terms of profitability, DGX's ROE is +0.13%, compared to STIM's ROE of -2.04%. Regarding short-term risk, DGX is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs NEO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NEO has a market cap of 219.04M. Regarding current trading prices, DGX is priced at $175.93, while NEO trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NEO's P/E ratio is -13.95. In terms of profitability, DGX's ROE is +0.13%, compared to NEO's ROE of -0.09%. Regarding short-term risk, DGX is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs ACRS Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ACRS has a market cap of 135.35M. Regarding current trading prices, DGX is priced at $175.93, while ACRS trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ACRS's P/E ratio is -0.73. In terms of profitability, DGX's ROE is +0.13%, compared to ACRS's ROE of -0.94%. Regarding short-term risk, DGX is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs GTH Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, GTH has a market cap of 127.29M. Regarding current trading prices, DGX is priced at $175.93, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas GTH's P/E ratio is -1.11. In terms of profitability, DGX's ROE is +0.13%, compared to GTH's ROE of +0.00%. Regarding short-term risk, DGX is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs GENE Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, GENE has a market cap of 111.24M. Regarding current trading prices, DGX is priced at $175.93, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas GENE's P/E ratio is -38.25. In terms of profitability, DGX's ROE is +0.13%, compared to GENE's ROE of -3.62%. Regarding short-term risk, DGX is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs XGN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, XGN has a market cap of 103.87M. Regarding current trading prices, DGX is priced at $175.93, while XGN trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas XGN's P/E ratio is -6.87. In terms of profitability, DGX's ROE is +0.13%, compared to XGN's ROE of -1.34%. Regarding short-term risk, DGX is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs MDXH Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, MDXH has a market cap of 89.10M. Regarding current trading prices, DGX is priced at $175.93, while MDXH trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas MDXH's P/E ratio is -1.55. In terms of profitability, DGX's ROE is +0.13%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, DGX is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs SERA Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, SERA has a market cap of 85.16M. Regarding current trading prices, DGX is priced at $175.93, while SERA trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas SERA's P/E ratio is -2.34. In terms of profitability, DGX's ROE is +0.13%, compared to SERA's ROE of -0.58%. Regarding short-term risk, DGX is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs NOTV Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NOTV has a market cap of 75.23M. Regarding current trading prices, DGX is priced at $175.93, while NOTV trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NOTV's P/E ratio is -0.48. In terms of profitability, DGX's ROE is +0.13%, compared to NOTV's ROE of -0.66%. Regarding short-term risk, DGX is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PRENW Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PRENW has a market cap of 69.52M. Regarding current trading prices, DGX is priced at $175.93, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PRENW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.13%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, DGX is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PRE Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PRE has a market cap of 68.43M. Regarding current trading prices, DGX is priced at $175.93, while PRE trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PRE's P/E ratio is -1.42. In terms of profitability, DGX's ROE is +0.13%, compared to PRE's ROE of -0.25%. Regarding short-term risk, DGX is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BDSX Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BDSX has a market cap of 52.63M. Regarding current trading prices, DGX is priced at $175.93, while BDSX trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BDSX's P/E ratio is -1.09. In terms of profitability, DGX's ROE is +0.13%, compared to BDSX's ROE of -2.16%. Regarding short-term risk, DGX is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs OPGN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, OPGN has a market cap of 50.04M. Regarding current trading prices, DGX is priced at $175.93, while OPGN trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas OPGN's P/E ratio is -0.32. In terms of profitability, DGX's ROE is +0.13%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, DGX is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs VNRX Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, VNRX has a market cap of 48.98M. Regarding current trading prices, DGX is priced at $175.93, while VNRX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas VNRX's P/E ratio is -1.57. In terms of profitability, DGX's ROE is +0.13%, compared to VNRX's ROE of +1.29%. Regarding short-term risk, DGX is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs DRIO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, DRIO has a market cap of 31.59M. Regarding current trading prices, DGX is priced at $175.93, while DRIO trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas DRIO's P/E ratio is -1.25. In terms of profitability, DGX's ROE is +0.13%, compared to DRIO's ROE of -0.47%. Regarding short-term risk, DGX is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs STRRP Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, STRRP has a market cap of 29.87M. Regarding current trading prices, DGX is priced at $175.93, while STRRP trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas STRRP's P/E ratio is -4.67. In terms of profitability, DGX's ROE is +0.13%, compared to STRRP's ROE of -0.18%. Regarding short-term risk, DGX is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs AKU Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, AKU has a market cap of 26.27M. Regarding current trading prices, DGX is priced at $175.93, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas AKU's P/E ratio is -0.13. In terms of profitability, DGX's ROE is +0.13%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DGX is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs ADVB Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ADVB has a market cap of 19.38M. Regarding current trading prices, DGX is priced at $175.93, while ADVB trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ADVB's P/E ratio is -6.40. In terms of profitability, DGX's ROE is +0.13%, compared to ADVB's ROE of -2.41%. Regarding short-term risk, DGX is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CEMI Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CEMI has a market cap of 16.71M. Regarding current trading prices, DGX is priced at $175.93, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DGX's ROE is +0.13%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DGX is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs ENZ Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ENZ has a market cap of 16.44M. Regarding current trading prices, DGX is priced at $175.93, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ENZ's P/E ratio is -2.24. In terms of profitability, DGX's ROE is +0.13%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, DGX is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PMD Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PMD has a market cap of 15.74M. Regarding current trading prices, DGX is priced at $175.93, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PMD's P/E ratio is -5.24. In terms of profitability, DGX's ROE is +0.13%, compared to PMD's ROE of -0.33%. Regarding short-term risk, DGX is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs ME Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ME has a market cap of 13.34M. Regarding current trading prices, DGX is priced at $175.93, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ME's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.13%, compared to ME's ROE of -3.04%. Regarding short-term risk, DGX is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BNGO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BNGO has a market cap of 12.13M. Regarding current trading prices, DGX is priced at $175.93, while BNGO trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BNGO's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.13%, compared to BNGO's ROE of -1.81%. Regarding short-term risk, DGX is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs PRPO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, PRPO has a market cap of 9.53M. Regarding current trading prices, DGX is priced at $175.93, while PRPO trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas PRPO's P/E ratio is -2.15. In terms of profitability, DGX's ROE is +0.13%, compared to PRPO's ROE of -0.35%. Regarding short-term risk, DGX is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CNTG Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CNTG has a market cap of 9.43M. Regarding current trading prices, DGX is priced at $175.93, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DGX's ROE is +0.13%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DGX is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs INBS Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, INBS has a market cap of 8.51M. Regarding current trading prices, DGX is priced at $175.93, while INBS trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas INBS's P/E ratio is 10.42. In terms of profitability, DGX's ROE is +0.13%, compared to INBS's ROE of -1.43%. Regarding short-term risk, DGX is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs STRR Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, STRR has a market cap of 7.89M. Regarding current trading prices, DGX is priced at $175.93, while STRR trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas STRR's P/E ratio is -0.74. In terms of profitability, DGX's ROE is +0.13%, compared to STRR's ROE of -0.18%. Regarding short-term risk, DGX is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs MYNZ Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, MYNZ has a market cap of 7.72M. Regarding current trading prices, DGX is priced at $175.93, while MYNZ trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas MYNZ's P/E ratio is -0.11. In terms of profitability, DGX's ROE is +0.13%, compared to MYNZ's ROE of -16.99%. Regarding short-term risk, DGX is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs NVTA Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NVTA has a market cap of 5.44M. Regarding current trading prices, DGX is priced at $175.93, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.13%, compared to NVTA's ROE of +1.79%. Regarding short-term risk, DGX is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BGLC Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BGLC has a market cap of 5.43M. Regarding current trading prices, DGX is priced at $175.93, while BGLC trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BGLC's P/E ratio is -3.36. In terms of profitability, DGX's ROE is +0.13%, compared to BGLC's ROE of -0.17%. Regarding short-term risk, DGX is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs APDN Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, APDN has a market cap of 5.39M. Regarding current trading prices, DGX is priced at $175.93, while APDN trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas APDN's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.13%, compared to APDN's ROE of -1.00%. Regarding short-term risk, DGX is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs LMDX Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, LMDX has a market cap of 5.10M. Regarding current trading prices, DGX is priced at $175.93, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.13%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs LMDXW Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, LMDXW has a market cap of 5.10M. Regarding current trading prices, DGX is priced at $175.93, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.13%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs CHEK Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, CHEK has a market cap of 4.77M. Regarding current trading prices, DGX is priced at $175.93, while CHEK trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas CHEK's P/E ratio is -0.38. In terms of profitability, DGX's ROE is +0.13%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, DGX is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs TTOO Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, TTOO has a market cap of 4.07M. Regarding current trading prices, DGX is priced at $175.93, while TTOO trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas TTOO's P/E ratio is -4.83. In terms of profitability, DGX's ROE is +0.13%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, DGX is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BIAF Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BIAF has a market cap of 3.65M. Regarding current trading prices, DGX is priced at $175.93, while BIAF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BIAF's P/E ratio is -0.27. In terms of profitability, DGX's ROE is +0.13%, compared to BIAF's ROE of -2.51%. Regarding short-term risk, DGX is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs DMTK Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, DMTK has a market cap of 3.29M. Regarding current trading prices, DGX is priced at $175.93, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.13%, compared to DMTK's ROE of -1.39%. Regarding short-term risk, DGX is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BIAFW Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BIAFW has a market cap of 3.05M. Regarding current trading prices, DGX is priced at $175.93, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BIAFW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.13%, compared to BIAFW's ROE of -2.51%. Regarding short-term risk, DGX is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs ISPC Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, ISPC has a market cap of 2.92M. Regarding current trading prices, DGX is priced at $175.93, while ISPC trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas ISPC's P/E ratio is -0.07. In terms of profitability, DGX's ROE is +0.13%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, DGX is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs AWH Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, AWH has a market cap of 2.89M. Regarding current trading prices, DGX is priced at $175.93, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas AWH's P/E ratio is -0.09. In terms of profitability, DGX's ROE is +0.13%, compared to AWH's ROE of +5.16%. Regarding short-term risk, DGX is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs BNR Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BNR has a market cap of 2.65M. Regarding current trading prices, DGX is priced at $175.93, while BNR trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BNR's P/E ratio is -0.53. In terms of profitability, DGX's ROE is +0.13%, compared to BNR's ROE of -0.53%. Regarding short-term risk, DGX is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs SQL Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, SQL has a market cap of 2.51M. Regarding current trading prices, DGX is priced at $175.93, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas SQL's P/E ratio is -0.40. In terms of profitability, DGX's ROE is +0.13%, compared to SQL's ROE of -0.67%. Regarding short-term risk, DGX is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs NDRA Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, NDRA has a market cap of 1.94M. Regarding current trading prices, DGX is priced at $175.93, while NDRA trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas NDRA's P/E ratio is -0.06. In terms of profitability, DGX's ROE is +0.13%, compared to NDRA's ROE of -2.11%. Regarding short-term risk, DGX is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs HTGM Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, HTGM has a market cap of 1.06M. Regarding current trading prices, DGX is priced at $175.93, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.13%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DGX is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs SQLLW Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, SQLLW has a market cap of 837087.00. Regarding current trading prices, DGX is priced at $175.93, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.13%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, DGX is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.
DGX vs BIOC Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, BIOC has a market cap of 450786.00. Regarding current trading prices, DGX is priced at $175.93, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.13%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DGX is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.
DGX vs TRIB Comparison
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 19.64B. In comparison, TRIB has a market cap of 415080.00. Regarding current trading prices, DGX is priced at $175.93, while TRIB trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.24, whereas TRIB's P/E ratio is -0.32. In terms of profitability, DGX's ROE is +0.13%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, DGX is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.